The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

被引:0
|
作者
Ryan T. Phan
Riccardo Dalla-Favera
机构
[1] Columbia University,Institute for Cancer Genetics and the Departments of Pathology and Genetics & Development
来源
Nature | 2004年 / 432卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The human proto-oncogene BCL6 encodes a BTB/POZ-zinc-finger transcriptional repressor that is necessary for germinal-centre formation and is implicated in the pathogenesis of B-cell lymphoma1,2,3. The precise function of BCL6 in germinal-centre development and lymphomagenesis is unclear because very few direct BCL6 target genes have been identified4,5,6,7. Here we report that BCL6 suppresses the expression of the p53 (also known as tp53) tumour suppressor gene and modulates DNA damage-induced apoptotic responses in germinal-centre B cells. BCL6 represses p53 transcription by binding two specific DNA sites within the p53 promoter region and, accordingly, p53 expression is absent in germinal-centre B cells where BCL6 is highly expressed. Suppression of BCL6 expression via specific short interfering RNA leads to increased levels of p53 messenger RNA and protein both under basal conditions and in response to DNA damage. Most notably, constitutive expression of BCL6 protects B cell lines from apoptosis induced by DNA damage. These results suggest that an important function of BCL6 is to allow germinal-centre B cells to tolerate the physiological DNA breaks required for immunoglobulin class switch recombination and somatic hypermutation without inducing a p53-dependent apoptotic response. These findings also imply that deregulated BCL6 expression contributes to lymphomagenesis in part by functional inactivation of p53.
引用
收藏
页码:635 / 639
页数:4
相关论文
共 50 条
  • [31] Roles of BCL6 in normal and transformed germinal center B cells
    Basso, Katia
    Dalla-Favera, Riccardo
    IMMUNOLOGICAL REVIEWS, 2012, 247 : 172 - 183
  • [32] Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells
    Saito, Yoshimasa
    Liang, Gangning
    Egger, Gerda
    Friedman, Jeffrey M.
    Chuang, Jody C.
    Coetzee, Gerhard A.
    Jones, Peter A.
    CANCER CELL, 2006, 9 (06) : 435 - 443
  • [33] S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition
    Ye, B. Hilda
    Chung, Elaine
    Pradhan, Kith
    Acuna-Villaorduna, Ana
    Wang, Yanhua
    Shastri, Aditi
    Madireddy, Advaitha
    Verma, Amit
    Sica, R. Alejandro
    Janakiram, Murali
    BLOOD, 2019, 134
  • [34] BCL6: Master Regulator of the Germinal Center Reaction and Key Oncogene in B Cell Lymphomagenesis
    Basso, Katia
    Dalla-Favera, Riccardo
    ADVANCES IN IMMUNOLOGY, VOL 105, 2010, 105 : 193 - 210
  • [35] Bcl6 and p53 gene expression predict survival in the small noncleaved cell lymphomas
    Chai, C
    Aoun, P
    Greiner, T
    Bishop, J
    Lynch, J
    Chan, W
    Bierman, P
    Gordon, B
    Vose, J
    Armitage, J
    Weisenburger, D
    LABORATORY INVESTIGATION, 1999, 79 (01) : 133A - 133A
  • [36] Mechanisms of inhibition of p53 function in tumours that express the Pax3 proto-oncogene
    Underwood, TJ
    Blaydes, JP
    Lillycrop, KA
    BRITISH JOURNAL OF SURGERY, 2005, 92 (10) : 1308 - 1308
  • [37] p53 downregulates CRKL proto-oncogene protein through miR-200 family
    Sasaki, Yasushi
    Tamura, Miyuki
    Kobashi, Kenta
    Takeda, Kousuke
    Nakagaki, Takafumi
    Idogawa, Masashi
    Tokino, Takashi
    CANCER RESEARCH, 2015, 75
  • [38] BCL6, p53 and molecular targeted therapy in B-cell lymphomas.
    Cerchietti, LCA
    Polo, JM
    Da Silva, GF
    Dowdy, SM
    Giorgio, CM
    Rita, SM
    Melnick, AM
    BLOOD, 2005, 106 (11) : 427A - 428A
  • [39] Expression of proto-oncogene c-myc, MDM2 and anti-oncogene p53 induced by different concentrations of formaldehyde
    Ding, S.-M. (dingsm@mail.ccnu.edu.cn), 1600, Chinese Society for Environmental Sciences (33):
  • [40] MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR/BCL6/p53 axis
    Srishti Srivastava
    Hima Makala
    Vikas Sharma
    Vaishali Suri
    Chitra Sarkar
    Ritu Kulshreshtha
    Cellular and Molecular Life Sciences, 2022, 79